Technical Analysis for NVAX - Novavax, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 170.471 | 7.82% | 12.37 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Down | Down |
| Historical NVAX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 9.02% | |
| MACD Bearish Centerline Cross | Bearish | 9.02% | |
| Expansion Pivot Sell Setup | Bearish Swing Setup | 9.02% | |
| Lower Bollinger Band Walk | Weakness | 9.02% | |
| Multiple of Ten Bearish | Other | 9.02% | |
| Multiple of Ten Bullish | Other | 9.02% | |
| Wide Bands | Range Expansion | 9.02% | |
| Below Lower BB | Weakness | 9.02% | |
| Down 3 Days in a Row | Weakness | 9.02% | |
| Lower Bollinger Band Touch | Weakness | 9.02% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Up 10% | about 1 hour ago | |
| Trending on StockTwits | about 2 hours ago | |
| 60 Minute Opening Range Breakout | about 2 hours ago | |
| Down 5% | about 3 hours ago | |
| 60 Minute Opening Range Breakdown | about 3 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 11/01/2021
Novavax, Inc. Description
Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases. The company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles (VLPs) and recombinant protein micelle vaccines. Its vaccine candidates target seasonal influenza, pandemic (H5N1) influenza, and respiratory syncytial virus (RSV). The company, through its joint venture, CPL Biologics Private Limited, engages in developing seasonal and pandemic influenza, and rabies vaccine candidates. The company has a licensing agreement with LG Life Sciences, Ltd. to use the company's VLP technology to develop and sell the influenza vaccines in South Korea and other countries; and a clinical development agreement with PATH Vaccine Solutions to develop RSV vaccine candidate. The company was founded in 1987 and is headquartered in Rockville, Maryland.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Development Infectious Diseases Influenza Coronavirus Vaccine Vaccination Influenza Vaccine Influenza Vaccines Rabies Seasonal Influenza Novavax
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 331.5388 |
| 52 Week Low | 6.77 |
| Average Volume | 4,560,316 |
| 200-Day Moving Average | 123.53 |
| 50-Day Moving Average | 187.95 |
| 20-Day Moving Average | 257.11 |
| 10-Day Moving Average | 224.69 |
| Average True Range | 25.65 |
| ADX | 31.04 |
| +DI | 18.35 |
| -DI | 42.98 |
| Chandelier Exit (Long, 3 ATRs ) | 254.60 |
| Chandelier Exit (Short, 3 ATRs ) | 224.33 |
| Upper Bollinger Band | 340.78 |
| Lower Bollinger Band | 173.43 |
| Percent B (%b) | -0.09 |
| BandWidth | 65.09 |
| MACD Line | -1.81 |
| MACD Signal Line | 14.48 |
| MACD Histogram | -16.291 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 220.08 | ||||
| Resistance 3 (R3) | 223.40 | 206.05 | 209.75 | ||
| Resistance 2 (R2) | 206.05 | 190.27 | 204.40 | 206.30 | |
| Resistance 1 (R1) | 182.08 | 180.52 | 173.41 | 178.76 | 202.86 |
| Pivot Point | 164.73 | 164.73 | 160.40 | 163.08 | 164.73 |
| Support 1 (S1) | 140.76 | 148.95 | 132.09 | 137.44 | 113.34 |
| Support 2 (S2) | 123.41 | 139.20 | 121.76 | 109.90 | |
| Support 3 (S3) | 99.44 | 123.41 | 106.45 | ||
| Support 4 (S4) | 96.12 |
